{
  "_template_version": "1.0",
  "_instructions": "Each asset gets its own file: {asset_name_lowercase}.json (e.g., kt621.json)",

  "assets": [
    {
      "name": "ASSET-001",
      "target": "TARGET",
      "mechanism": "Mechanism description",
      "modality": "Small molecule",
      "stage": "Phase 2",
      "lead_indication": "Primary indication",
      "partner": null,

      "clinical_development": {
        "current_stage": "Phase 2",
        "indications_in_development": [
          "Indication 1",
          "Indication 2"
        ],
        "market_opportunity": "$XB market"
      },

      "trials": [
        {
          "name": "Trial Name",
          "nct_id": "NCT00000000",
          "phase": "Phase 2",
          "status": "Ongoing",
          "indication": "Indication",
          "design": "Randomized, double-blind, placebo-controlled",
          "population": "Patient population description",
          "n_target": 100,
          "arms": [
            {"name": "Placebo", "n": 33},
            {"name": "Asset Low Dose", "dose": "Xmg", "frequency": "QD", "n": 33},
            {"name": "Asset High Dose", "dose": "Ymg", "frequency": "QD", "n": 33}
          ],
          "primary_endpoint": "Primary endpoint description",
          "secondary_endpoints": ["Secondary 1", "Secondary 2"],
          "duration": "X weeks",
          "endpoints": [
            {
              "name": "Endpoint Name",
              "category": "primary",
              "result": "Result value",
              "dose_group": "Dose group",
              "timepoint": "Week X",
              "p_value": 0.01,
              "notes": "Additional context"
            }
          ],
          "safety": "Safety summary",
          "data_expected": "Q1 2027"
        }
      ],

      "investment_thesis": [
        "Asset-specific thesis point 1",
        "Asset-specific thesis point 2"
      ],

      "key_risks": [
        "Asset-specific risk 1",
        "Asset-specific risk 2"
      ],

      "upcoming_catalysts": [
        {"event": "Catalyst description", "timing": "Q1 2027"}
      ]
    }
  ]
}
